Abstract
Tumour necrosis factor-α [TNF-α] inhibitors have revolutionised the management of chronic inflammatory conditions. A number of cutaneous adverse events have been reported with TNF inhibition, including vasculitis. Most reactions are mild and rarely warrant treatment withdrawal. Here we describe a patient with Crohn's disease treated with adalimumab in whom severe multivisceral Henoch-Schönlein purpura developed, including neurological involvement, requiring definitive TNF blocker withdrawal.
Keywords:
Crohn’s disease; Henoch-Schönlein purpura; adalimumab; endoscopy; pathology.
Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].
MeSH terms
-
Adalimumab / administration & dosage
-
Adalimumab / adverse effects*
-
Administration, Intravenous
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / adverse effects
-
Crohn Disease / diagnosis
-
Crohn Disease / drug therapy*
-
Dose-Response Relationship, Drug
-
Electromyography / methods
-
Endoscopy, Gastrointestinal / methods
-
Female
-
Gastrointestinal Hemorrhage* / diagnosis
-
Gastrointestinal Hemorrhage* / etiology
-
Glucocorticoids / administration & dosage*
-
Humans
-
IgA Vasculitis* / diagnosis
-
IgA Vasculitis* / etiology
-
IgA Vasculitis* / physiopathology
-
IgA Vasculitis* / therapy
-
Peripheral Nervous System Diseases* / diagnosis
-
Peripheral Nervous System Diseases* / etiology
-
Severity of Illness Index
-
Skin / pathology
-
Treatment Outcome
-
Tumor Necrosis Factor Inhibitors / administration & dosage
-
Tumor Necrosis Factor Inhibitors / adverse effects
-
Young Adult
Substances
-
Anti-Inflammatory Agents
-
Glucocorticoids
-
Tumor Necrosis Factor Inhibitors
-
Adalimumab